Evidence map›Paper›PMID 39434025›Full record

ArticleBMC infectious diseases2024

Critical resistance to carbapenem and aminoglycosides in Pseudomonas aeruginosa: spread of bla

Behnaz Soltani, Roya Ahmadrajabi, Davood Kalantar-Neyestanaki

Abstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Indian Society of Critical Care Medicine Guidelines on Evidence-based Recommendations for the Treatment of Carbapenem-resistant Enterobacterales, Carbapenem-resistantIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026
    Article
  2. Article
  3. Mechanisms ofMedicina (Kaunas, Lithuania) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. TRAIL-mediated armA upregulation enhances the drug resistance ofAmerican journal of translational research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Behnaz SoltaniMedical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Roya AhmadrajabiMedical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Davood Kalantar-NeyestanakiMedical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran. d.kalantar@kmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the main Gram-negative bacterium causes of infections in hospital settings, and the spread of them is a significant challenge to public health.

methodsA total of 30 non-duplicate isolates of CRPA were collected. Antibacterial susceptibility of isolates to antibiotic agents, AmpC β-lactamase production, and biofilm formation were determined. Minimum biofilm inhibitory concentrations (MBIC) of isolates to cefepime (FEP), imipenem (IPM), ceftazidime (CAZ), and meropenem (MEM) were evaluated with/without cloxacillin (CLX). The carbapenemase and 16 S rRNA methylase genes were identified by PCR, and the transcription levels of oprD, ampC, and mexA genes were determined by quantitative real-time PCR (qPCR). ERIC-PCR was used to detect genetic relationships among isolates.

resultsAll isolates were multidrug resistant (MDR) and strong biofilm producers. The resistance genes including bla

conclusionIn this study, we reported the spread of different clones of CRPA harboring co-existence of various carbapenemase genes with armA 16 S rRNA methylase for the first time in Kerman, Iran. Also, our isolates had several mechanisms of resistance to carbapenems as well as ability biofilm formation along with resistance to aminoglycosides, the further spread of which could cause serious challenges in our hospital settings. Therefore, serious monitoring is necessary to reduce their prevalence.

Indexed as

AminoglycosidesAnti-Bacterial Agentsbeta-LactamasesBiofilmsCarbapenemsPseudomonas aeruginosaPseudomonas InfectionsBacterial ProteinsDrug Resistance, Multiple, BacterialHumansIranMethyltransferasesMicrobial Sensitivity TestsAminoglycosidesAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsMethyltransferasesAmpC β-lactamaseBiofilmCarbapenemaseEfflux pumpoprDPseudomonas aeruginosa

Identifiers

PMID39434025
PMCPMC11494745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.